Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

21
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
21
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

21
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
21
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

17
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
17
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

16
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
16
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

20
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
20
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

23
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
23

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anisotropic Black Phosphorus Synaptic Device for Neuromorphic Applications.

Advanced materials (Deerfield Beach, Fla.)·2016
Same author

An accurate clone-based haplotyping method by overlapping pool sequencing.

Nucleic acids research·2016
Same author

Upregulation of proangiogenic factors expression in the synovium of temporomandibular joint condylar hyperplasia.

Oral surgery, oral medicine, oral pathology and oral radiology·2016
Same author

Synthesis and Applications of π-Extended Naphthalene Diimides.

Chemical record (New York, N.Y.)·2016
Same author

Observation of the Singly Cabibbo-Suppressed Decay D^{+}→ωπ^{+} and Evidence for D^{0}→ωπ^{0}.

Physical review letters·2016
Same author

Circular RNAs: a new frontier in the study of human diseases.

Journal of medical genetics·2016

Related Experiment Video

Updated: Feb 15, 2026

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
18:57

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers

Published on: October 17, 2013

47.4K

Dendritic phospholipid-based drug delivery systems.

Lei Jiang1, Weizhi Chen, Sensen Zhou

  • 1MOE Key Laboratory of High Performance Polymer Materials and Technology, and Department of Polymer Science & Engineering, College of Chemistry & Chemical Engineering, Nanjing University, Nanjing, 210093, P. R. China. jiangx@nju.edu.cn weiwu@nju.edu.cn.

Biomaterials Science
|January 27, 2018
PubMed
Summary
This summary is machine-generated.

New dendritic phospholipid nanocarriers show improved drug delivery. Higher generation carriers (DPN-3) exhibit enhanced cell penetration and cytotoxicity for potential clinical applications.

More Related Videos

A Fluorescence-based Assay of Phospholipid Scramblase Activity
09:52

A Fluorescence-based Assay of Phospholipid Scramblase Activity

Published on: September 20, 2016

14.7K
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

31.5K

Related Experiment Videos

Last Updated: Feb 15, 2026

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
18:57

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers

Published on: October 17, 2013

47.4K
A Fluorescence-based Assay of Phospholipid Scramblase Activity
09:52

A Fluorescence-based Assay of Phospholipid Scramblase Activity

Published on: September 20, 2016

14.7K
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

31.5K

Area of Science:

  • Materials Science
  • Nanotechnology
  • Biomedical Engineering

Background:

  • Dendritic phospholipids offer unique structures for drug delivery systems.
  • Tailoring hydrophilic peripheries influences self-assembly and performance.
  • Developing efficient and safe nanocarriers is crucial for clinical translation.

Purpose of the Study:

  • To synthesize and characterize novel dendritic phospholipid compounds (DPL-1 to DPL-3).
  • To prepare and evaluate dendritic phospholipid nanocarriers (DPN-2 and DPN-3) for drug delivery.
  • To investigate the impact of hydrophilic peripheral structure on nanocarrier biological performance and drug delivery efficiency.

Main Methods:

  • Synthesis of dendritic poly(l-lysine) phospholipids.
  • Preparation and characterization of nanocarriers (size, TEM, CD spectrum).
  • In vitro cytotoxicity, cell internalization, and multicellular spheroid penetration studies.

Main Results:

  • Dendritic phospholipid compounds DPL-2 and DPL-3 self-assembled into nanocarriers (DPN-2, DPN-3).
  • DOX-loaded DPN-3 demonstrated superior cytotoxicity against 4T1 and BGC823 cells compared to DPN-2.
  • DPN-3 exhibited enhanced cell internalization and 4T1 multicellular spheroid penetration.

Conclusions:

  • The hydrophilic block composition significantly affects nanocarrier self-assembly, properties, and delivery efficiency.
  • Dendritic phospholipid nanocarriers show promise for high-efficiency, low-cytotoxicity drug delivery systems.
  • This research provides a foundation for developing advanced drug delivery systems for clinical use.